The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industryThe Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 37 novel products in 2021Additionally, last year in 2020, the US FDA…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyCadila expanded its footprints in India with the launch of its two biosimilars Bevaro (bevacizumab, biosimilar) and Ritucad (rituximab, biosimilar)Our team at PharmaShots has summarized 9 key events of the biosimilar space of July 20201. Samsung…

